Anti-Prostate Cancer Agents

Name: Anti-Prostate Cancer Agents
Price: 200 USD
Availability: InStock
ISBN: 9780443235856

by Qiao-Hong Chen

1st Edition

Publisher: Elsevier

(0 reviews)

Oncology

Compare Prices

VitalSourceLifetime Access$200.00 AmazonKindle$190.00 Best PriceeTextShelfPDF$38.00

Book Details

Print ISBN	9780443235856
eText ISBN	9780443235863
Publisher	Elsevier
Publishing Year	2025
Edition	1st Edition
Language	English
Pages	438

Anti-Prostate Cancer Agents, 1st Edition, provides a comprehensive overview of the drug development pipeline for prostate malignancies. The volume examines therapeutic candidate design from early discovery and synthetic evaluation to clinical applications.

The work traces therapeutic evolution from foundational androgen deprivation therapy to modern androgen receptor antagonists and degraders. It details structure-activity relationships, synthetic studies, molecular targets, and mechanisms of action to explain how chemical alterations influence biological effectiveness.

This text provides a targeted reference for researchers in medicinal chemistry, bioorganic chemistry, chemical biology, and biomedical sciences, as well as graduate students engaged in drug discovery.

Chapter 1: Introduction: Overview of prostate cancer
Chapter 2: FDA-approved therapeutics and diagnostics for prostate cancer
Chapter 3: Androgen deprivation therapy
Chapter 4: Antiprostate cancer agents interacting with topoisomerase II
Chapter 5: Microtubule-stabilizing compounds as antiprostate cancer agents
Chapter 6: Comprehensive insights into androgen receptor structure, signaling, and targeted therapeutics in prostate cancer
Chapter 7: Androgen biosynthesis suppressors in prostate cancer therapy
Chapter 8: Androgen receptor antagonists: From steroidal to first-generation nonsteroidal agents
Chapter 9: Second-generation nonsteroidal androgen receptor antagonists
Chapter 10: Antiprostate cancer agents: Focus on N-terminal domain of androgen receptor
Chapter 11: Androgen receptor degraders as antiprostate cancer agents
Chapter 12: Radiotherapeutics in prostate cancer therapy
Chapter 13: Immunotherapy for prostate cancer
Chapter 14: Radiosensitizers for prostate cancer therapy
Chapter 15: Prostate-specific membrane antigen in prostate cancer: Diagnostic and therapeutic innovations
Chapter 16: PARP inhibitors in prostate cancer: Mechanism, therapeutics, and clinical perspectives
Chapter 17: Combination therapies for prostate cancer: Synergistic approaches
Chapter 18: Future directions